Buchumschlag

Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer: final results of the EUCROSS trial

Background - In 2019, we reported the first efficacy and safety analysis of EUCROSS, a phase II trial investigating crizotinib in ROS1 fusion-positive lung cancer. At that time, overall survival (OS) was immature and the effect of crizotinib on intracranial disease control remained unclear. Here, we...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Michels, Sebastian (VerfasserIn) , Massutí, B. (VerfasserIn) , Vasyliv, I. (VerfasserIn) , Stratmann, J. (VerfasserIn) , Frank, J. (VerfasserIn) , Adams, A. (VerfasserIn) , Felip, E. (VerfasserIn) , Grohé, C. (VerfasserIn) , Rodriguez-Abreu, D. (VerfasserIn) , Bischoff, Helge (VerfasserIn) , Carcereny i Costa, E. (VerfasserIn) , Corral, J. (VerfasserIn) , Pereira, E. (VerfasserIn) , Fassunke, J. (VerfasserIn) , Fischer, R. N. (VerfasserIn) , Insa, A. (VerfasserIn) , Koleczko, S. (VerfasserIn) , Nogova, L. (VerfasserIn) , Reck, M. (VerfasserIn) , Reutter, T. (VerfasserIn) , Riedel, R. (VerfasserIn) , Schaufler, D. (VerfasserIn) , Scheffler, M. (VerfasserIn) , Weisthoff, M. (VerfasserIn) , Provencio, M. (VerfasserIn) , Merkelbach-Bruse, S. (VerfasserIn) , Hellmich, M. (VerfasserIn) , Sebastian, M. (VerfasserIn) , Büttner, R. (VerfasserIn) , Persigehl, T. (VerfasserIn) , Rosell, R. (VerfasserIn) , Wolf, J. (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: February 2024
In: ESMO open
Year: 2024, Jahrgang: 9, Heft: 2, Pages: 1-10
ISSN:2059-7029
DOI:10.1016/j.esmoop.2024.102237
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.esmoop.2024.102237
Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S205970292400005X
Volltext
Verfasserangaben:S. Michels, B. Massutí, I. Vasyliv, J. Stratmann, J. Frank, A. Adams, E. Felip, C. Grohé, D. Rodriguez-Abreu, H. Bischoff, E. Carcereny i Costa, J. Corral, E. Pereira, J. Fassunke, R.N. Fischer, A. Insa, S. Koleczko, L. Nogova, M. Reck, T. Reutter, R. Riedel, D. Schaufler, M. Scheffler, M. Weisthoff, M. Provencio, S. Merkelbach-Bruse, M. Hellmich, M. Sebastian, R. Büttner, T. Persigehl, R. Rosell & J. Wolf

MARC

LEADER 00000caa a2200000 c 4500
001 1894166329
003 DE-627
005 20241205150418.0
007 cr uuu---uuuuu
008 240705s2024 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.esmoop.2024.102237  |2 doi 
035 |a (DE-627)1894166329 
035 |a (DE-599)KXP1894166329 
035 |a (OCoLC)1475301503 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Michels, Sebastian  |d 1987-  |e VerfasserIn  |0 (DE-588)1123245789  |0 (DE-627)876604203  |0 (DE-576)48170809X  |4 aut 
245 1 0 |a Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer  |b final results of the EUCROSS trial  |c S. Michels, B. Massutí, I. Vasyliv, J. Stratmann, J. Frank, A. Adams, E. Felip, C. Grohé, D. Rodriguez-Abreu, H. Bischoff, E. Carcereny i Costa, J. Corral, E. Pereira, J. Fassunke, R.N. Fischer, A. Insa, S. Koleczko, L. Nogova, M. Reck, T. Reutter, R. Riedel, D. Schaufler, M. Scheffler, M. Weisthoff, M. Provencio, S. Merkelbach-Bruse, M. Hellmich, M. Sebastian, R. Büttner, T. Persigehl, R. Rosell & J. Wolf 
264 1 |c February 2024 
300 |b Illustrationen 
300 |a 10 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 05.07.2024 
500 |a Online verfügbar 12 February 2024, Version des Artikels 12 February 2024 
520 |a Background - In 2019, we reported the first efficacy and safety analysis of EUCROSS, a phase II trial investigating crizotinib in ROS1 fusion-positive lung cancer. At that time, overall survival (OS) was immature and the effect of crizotinib on intracranial disease control remained unclear. Here, we present the final analysis of OS, systemic and intracranial activity, and the impact of co-occurring aberrations. - Materials and methods - EUCROSS was a prospective, single-arm, phase II trial. The primary endpoint was best overall response rate (ORR) using RECIST 1.1. Secondary and exploratory endpoints were progression-free survival (PFS), OS, and efficacy in pre-defined subgroups. - Results - Median OS of the intention-to-treat population (N = 34) was 54.8 months [95% confidence interval (CI) 20.3 months-not reached (NR); median follow-up 81.4 months] and median all-cause PFS of the response-evaluable population (N = 30) was 19.4 months (95% CI 10.1-32.2 months). Time on treatment was significantly correlated with OS (R = 0.82; P < 0.0001). Patients with co-occurring TP53 aberrations (28%) had a significantly shorter OS [hazard ratio (HR) 11; 95% CI 2.0-56.0; P = 0.006] and all-cause PFS (HR 4.2; 95% CI 1.2-15; P = 0.025). Patients with central nervous system (CNS) involvement at baseline (N = 6; 20%) had a numerically shorter median OS and all-cause PFS. Median intracranial PFS was 32.2 months (95% CI 23.7 months-NR) and the rate of isolated CNS progression was 24%. - Conclusions - Our final analysis proves the efficacy of crizotinib in ROS1-positive lung cancer, but also highlights the devastating impact of TP53 mutations on survival and treatment efficacy. Additionally, our data show that CNS disease control is durable and the risk of CNS progression while on crizotinib treatment is low. 
650 4 |a crizotinib 
650 4 |a EUCROSS 
650 4 |a lung cancer 
650 4 |a overall survival 
650 4 |a ROS1 
700 1 |a Massutí, B.  |e VerfasserIn  |4 aut 
700 1 |a Vasyliv, I.  |e VerfasserIn  |4 aut 
700 1 |a Stratmann, J.  |e VerfasserIn  |4 aut 
700 1 |a Frank, J.  |e VerfasserIn  |4 aut 
700 1 |a Adams, A.  |e VerfasserIn  |4 aut 
700 1 |a Felip, E.  |e VerfasserIn  |4 aut 
700 1 |a Grohé, C.  |e VerfasserIn  |4 aut 
700 1 |a Rodriguez-Abreu, D.  |e VerfasserIn  |4 aut 
700 1 |a Bischoff, Helge  |d 1958-  |e VerfasserIn  |0 (DE-588)111184576  |0 (DE-627)389658286  |0 (DE-576)167287249  |4 aut 
700 1 |a Carcereny i Costa, E.  |e VerfasserIn  |4 aut 
700 1 |a Corral, J.  |e VerfasserIn  |4 aut 
700 1 |a Pereira, E.  |e VerfasserIn  |4 aut 
700 1 |a Fassunke, J.  |e VerfasserIn  |4 aut 
700 1 |a Fischer, R. N.  |e VerfasserIn  |4 aut 
700 1 |a Insa, A.  |e VerfasserIn  |4 aut 
700 1 |a Koleczko, S.  |e VerfasserIn  |4 aut 
700 1 |a Nogova, L.  |e VerfasserIn  |4 aut 
700 1 |a Reck, M.  |e VerfasserIn  |4 aut 
700 1 |a Reutter, T.  |e VerfasserIn  |4 aut 
700 1 |a Riedel, R.  |e VerfasserIn  |4 aut 
700 1 |a Schaufler, D.  |e VerfasserIn  |4 aut 
700 1 |a Scheffler, M.  |e VerfasserIn  |4 aut 
700 1 |a Weisthoff, M.  |e VerfasserIn  |4 aut 
700 1 |a Provencio, M.  |e VerfasserIn  |4 aut 
700 1 |a Merkelbach-Bruse, S.  |e VerfasserIn  |4 aut 
700 1 |a Hellmich, M.  |e VerfasserIn  |4 aut 
700 1 |a Sebastian, M.  |e VerfasserIn  |4 aut 
700 1 |a Büttner, R.  |e VerfasserIn  |4 aut 
700 1 |a Persigehl, T.  |e VerfasserIn  |4 aut 
700 1 |a Rosell, R.  |e VerfasserIn  |4 aut 
700 1 |a Wolf, J.  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t ESMO open  |d [London] : Elsevier, 2016  |g 9(2024), 2 vom: Feb., Artikel-ID 102237, Seite 1-10  |h Online-Ressource  |w (DE-627)84705344X  |w (DE-600)2844985-X  |w (DE-576)454658516  |x 2059-7029  |7 nnas  |a Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer final results of the EUCROSS trial 
773 1 8 |g volume:9  |g year:2024  |g number:2  |g month:02  |g elocationid:102237  |g pages:1-10  |g extent:10  |a Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer final results of the EUCROSS trial 
856 4 0 |u https://doi.org/10.1016/j.esmoop.2024.102237  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://www.sciencedirect.com/science/article/pii/S205970292400005X  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20240705 
993 |a Article 
994 |a 2024 
998 |g 111184576  |a Bischoff, Helge  |m 111184576:Bischoff, Helge  |d 910000  |d 950000  |d 950900  |e 910000PB111184576  |e 950000PB111184576  |e 950900PB111184576  |k 0/910000/  |k 1/910000/950000/  |k 2/910000/950000/950900/  |p 10 
999 |a KXP-PPN1894166329  |e 4547122768 
BIB |a Y 
SER |a journal 
JSO |a {"person":[{"display":"Michels, Sebastian","role":"aut","given":"Sebastian","roleDisplay":"VerfasserIn","family":"Michels"},{"family":"Massutí","roleDisplay":"VerfasserIn","given":"B.","display":"Massutí, B.","role":"aut"},{"display":"Vasyliv, I.","role":"aut","given":"I.","family":"Vasyliv","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","family":"Stratmann","given":"J.","display":"Stratmann, J.","role":"aut"},{"roleDisplay":"VerfasserIn","family":"Frank","given":"J.","role":"aut","display":"Frank, J."},{"display":"Adams, A.","role":"aut","given":"A.","family":"Adams","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","family":"Felip","display":"Felip, E.","role":"aut","given":"E."},{"roleDisplay":"VerfasserIn","family":"Grohé","role":"aut","display":"Grohé, C.","given":"C."},{"given":"D.","role":"aut","display":"Rodriguez-Abreu, D.","roleDisplay":"VerfasserIn","family":"Rodriguez-Abreu"},{"given":"Helge","role":"aut","display":"Bischoff, Helge","family":"Bischoff","roleDisplay":"VerfasserIn"},{"display":"Carcereny i Costa, E.","role":"aut","given":"E.","roleDisplay":"VerfasserIn","family":"Carcereny i Costa"},{"family":"Corral","roleDisplay":"VerfasserIn","given":"J.","display":"Corral, J.","role":"aut"},{"given":"E.","role":"aut","display":"Pereira, E.","roleDisplay":"VerfasserIn","family":"Pereira"},{"family":"Fassunke","roleDisplay":"VerfasserIn","given":"J.","display":"Fassunke, J.","role":"aut"},{"given":"R. N.","display":"Fischer, R. N.","role":"aut","family":"Fischer","roleDisplay":"VerfasserIn"},{"family":"Insa","roleDisplay":"VerfasserIn","given":"A.","role":"aut","display":"Insa, A."},{"given":"S.","role":"aut","display":"Koleczko, S.","roleDisplay":"VerfasserIn","family":"Koleczko"},{"family":"Nogova","roleDisplay":"VerfasserIn","given":"L.","display":"Nogova, L.","role":"aut"},{"roleDisplay":"VerfasserIn","family":"Reck","display":"Reck, M.","role":"aut","given":"M."},{"given":"T.","display":"Reutter, T.","role":"aut","roleDisplay":"VerfasserIn","family":"Reutter"},{"display":"Riedel, R.","role":"aut","given":"R.","family":"Riedel","roleDisplay":"VerfasserIn"},{"given":"D.","role":"aut","display":"Schaufler, D.","family":"Schaufler","roleDisplay":"VerfasserIn"},{"role":"aut","display":"Scheffler, M.","given":"M.","family":"Scheffler","roleDisplay":"VerfasserIn"},{"family":"Weisthoff","roleDisplay":"VerfasserIn","display":"Weisthoff, M.","role":"aut","given":"M."},{"family":"Provencio","roleDisplay":"VerfasserIn","given":"M.","display":"Provencio, M.","role":"aut"},{"family":"Merkelbach-Bruse","roleDisplay":"VerfasserIn","role":"aut","display":"Merkelbach-Bruse, S.","given":"S."},{"given":"M.","role":"aut","display":"Hellmich, M.","family":"Hellmich","roleDisplay":"VerfasserIn"},{"given":"M.","display":"Sebastian, M.","role":"aut","family":"Sebastian","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","family":"Büttner","role":"aut","display":"Büttner, R.","given":"R."},{"roleDisplay":"VerfasserIn","family":"Persigehl","given":"T.","role":"aut","display":"Persigehl, T."},{"display":"Rosell, R.","role":"aut","given":"R.","family":"Rosell","roleDisplay":"VerfasserIn"},{"given":"J.","role":"aut","display":"Wolf, J.","roleDisplay":"VerfasserIn","family":"Wolf"}],"physDesc":[{"noteIll":"Illustrationen","extent":"10 S."}],"name":{"displayForm":["S. Michels, B. Massutí, I. Vasyliv, J. Stratmann, J. Frank, A. Adams, E. Felip, C. Grohé, D. Rodriguez-Abreu, H. Bischoff, E. Carcereny i Costa, J. Corral, E. Pereira, J. Fassunke, R.N. Fischer, A. Insa, S. Koleczko, L. Nogova, M. Reck, T. Reutter, R. Riedel, D. Schaufler, M. Scheffler, M. Weisthoff, M. Provencio, S. Merkelbach-Bruse, M. Hellmich, M. Sebastian, R. Büttner, T. Persigehl, R. Rosell & J. Wolf"]},"relHost":[{"part":{"volume":"9","issue":"2","text":"9(2024), 2 vom: Feb., Artikel-ID 102237, Seite 1-10","pages":"1-10","extent":"10","year":"2024"},"name":{"displayForm":["European Society for Medical Oncology"]},"physDesc":[{"extent":"Online-Ressource"}],"language":["eng"],"origin":[{"publisher":"Elsevier ; BMJ","publisherPlace":"[London] ; London","dateIssuedKey":"2016","dateIssuedDisp":"2016-"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"title":[{"title_sort":"ESMO open","title":"ESMO open","subtitle":"cancer horizons"}],"id":{"eki":["84705344X"],"zdb":["2844985-X"],"issn":["2059-7029"]},"note":["Gesehen am 13.06.24"],"disp":"Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer final results of the EUCROSS trialESMO open","pubHistory":["1.2016 -"],"corporate":[{"roleDisplay":"Herausgebendes Organ","role":"isb","display":"European Society for Medical Oncology"}],"recId":"84705344X"}],"language":["eng"],"origin":[{"dateIssuedKey":"2024","dateIssuedDisp":"February 2024"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"id":{"doi":["10.1016/j.esmoop.2024.102237"],"eki":["1894166329"]},"title":[{"subtitle":"final results of the EUCROSS trial","title_sort":"Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer","title":"Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer"}],"recId":"1894166329","note":["Gesehen am 05.07.2024","Online verfügbar 12 February 2024, Version des Artikels 12 February 2024"]} 
SRT |a MICHELSSEBOVERALLSUR2024 

Ähnliche Einträge